Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(...

全面介紹

Na minha lista:
書目詳細資料
發表在:Neurol Med Chir (Tokyo)
Main Authors: AOKI, Tomokazu, ARAKAWA, Yoshiki, UEBA, Tetsuya, ODA, Masashi, NISHIDA, Namiko, AKIYAMA, Yukinori, TSUKAHARA, Tetsuya, IWASAKI, Koichi, MIKUNI, Nobuhiro, MIYAMOTO, Susumu
格式: Artigo
語言:Inglês
出版: The Japan Neurosurgical Society 2017
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5243161/
https://ncbi.nlm.nih.gov/pubmed/27725524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2176/nmc.oa.2016-0162
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍